Drug intelligence / Profile preview

trepulimab

Development stage: Preclinical

Overview

Trepulimab is an investigational immunotherapy being studied in combination with short-course radiochemotherapy for the neoadjuvant treatment of resectable locally advanced esophageal squamous cell carcinoma. The specific mechanism of action and developer for trepulimab as a distinct entity are not publicly available.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on trepulimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trepulimab.

Explore the full profile